Abstract

Gastrointestinal symptoms are common in COVID-19 patients but the nature of the gut immune response to SARS-CoV-2 remains poorly characterized, partly due to the difficulty of obtaining biopsy specimens from infected individuals. In lieu of tissue samples, we measured cytokines, inflammatory markers, viral RNA, microbiome composition, and antibody responses in stool samples from a cohort of 44 hospitalized COVID-19 patients. SARS-CoV-2 RNA was detected in stool of 41% of patients and more frequently in patients with diarrhea. Patients who survived had lower fecal viral RNA than those who died. Strains isolated from stool and nasopharynx of an individual were the same. Compared to uninfected controls, COVID-19 patients had higher fecal levels of IL-8 and lower levels of fecal IL-10. Stool IL-23 was higher in patients with more severe COVID-19 disease, and we found evidence of intestinal virus-specific IgA responses associated with more severe disease. We provide evidence for an ongoing humeral immune response to SARS-CoV-2 in the gastrointestinal tract, but little evidence of overt inflammation.

Highlights

  • SARS-CoV-2 (Severe Acute Respiratory Syndrome CoronaVirus 2) a novel Betacoronavirus that causes COVID19 (Coronavirus Disease 2019)) emerged in Wuhan, China December ­20191 and rapidly spread, leading to a worldwide pandemic

  • We collected stool samples from 44 symptomatic COVID-19 patients hospitalized in New York City between April 15 and May 21 2020 (Table S1 and Date file S1)

  • During hospitalization 10 of the 22 (45.5%) patients who presented with moderate disease developed severe COVID-19 disease, while none of the patients who presented with mild symptoms had clinical worsening during hospitalization (Table 1 and Date file S1)

Read more

Summary

Introduction

SARS-CoV-2 (Severe Acute Respiratory Syndrome CoronaVirus 2) a novel Betacoronavirus that causes COVID19 (Coronavirus Disease 2019)) emerged in Wuhan, China December ­20191 and rapidly spread, leading to a worldwide pandemic. 2 (ACE2), the putative receptor for SARS-CoV-2, is highly expressed on the small intestinal e­ pithelium[9,10] and viral RNA has been detected in the stools of patients with COVID-19 for prolonged periods of ­time[11,12]. Systemic immune dysregulation is associated with severe COVID-19 infection, as high serum interleukin (IL)-6 IL-8, IL-10 and tumor necrosis factor (TNFα) correlate with increased disease severity and poor ­prognoses[21,22,23,24,25,26]

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call